At a glance

ClinicalIndex Comparison Record

N/ACompleted· 84 enrolled

Drug / intervention

Guanfacine +1 moredrug

Likely dose

Guanfacine 1 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02882854

NCT02882854N/ACompleted

Compare CT.gov

Guanfacine for PONV and Pain After Sinus Surgery

Vanderbilt University Medical Center·interventional·Posted Aug 30, 2016·Updated Jan 3, 2019

In Brief

A clinical study evaluating Guanfacine and Placebo for Postoperative Nausea and Vomiting and Pain, Postoperative. Completed, enrolled 84 participants across 1 site.

Detailed Summary

Postoperative nausea and vomiting (PONV) and pain are the most common causes of Post Anesthesia Care Unit (PACU) discharge delay, with untreated PONV occurring in 20-30% of post-surgical patients. The effect of guanfacine (GF) administration on pain and nausea scores will be assessed with two groups. One group will receive 1 mg of GF to take orally and the other group will receive a similar appearing placebo (containing no drug) to take orally.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPostoperative Nausea and Vomiting, Pain, Postoperative

CountriesUnited States

Collaborators--

Timeline

N/ACompletedFinished

2017201820192020202120222023202420252026

First PostedAug 2016

Enrollment StartNov 2016

Primary CompletionFeb 2017

TodayJul 2026

First PostedAug 30, 2016

Enrollment StartNov 1, 2016

Primary CompletionFeb 1, 2017

TodayJul 2, 2026

Enrollment to primary: 3 monthsPosted 9.8 years ago

Interventions

Guanfacinedrug

Patients will receive 1 mg of guanfacine to take orally.

Placebodrug

Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.